HHS guidance specifying that health plans sold through Affordable Care Act exchanges are not government programs and thus not subject to restrictions on drugmaker copay coupons will ultimately raise prices for consumers, some industry observers say. AHIP said it is reviewing the ruling but noted that copay coupons undermine efforts to drive down costs and reward quality.

Related Summaries